Dimitris Voliotis
Chief Medical OfficerDr. Dimitris Voliotis, M.D. is Chief Medical Officer of Radiopharm Theranostics Limited from August 20, 2024. Dr. Voliotis was Senior Vice President of Clinical Development at Convergent Therapeutics, Inc. since September 2023 until July 2024. Dr. Voliotis served as the Senior Vice President, Head of Clinical Development at Zentalis Pharmaceuticals, Inc. since February 2020 until September 2022, a consultant in oncology drug development with Magnesia Partners Consulting LLC, advising across clinical development and regulatory strategy since September 2022. Dr. Voliotis served as Chief Development Officer and Member of Executive Board at CureVac AG January 2019 until December 2019. He worked with Japanese company Eisai Inc, from September 2014 to January 2019. Dr. Voliotis oversaw preclinical and clinical development activities for prophylactic vaccines, rare diseases/molecular therapies and oncology. He has worked both in the U.S. as well as in Europe and was last at Eisai Inc., as Senior Vice President & Head, Global Clinical Development for the global Oncology Business Group from January 2016 to January 2019. At Eisai, Dr. Voliotis had previously served as Vice President, Therapeutic Area Head and Head of Global Clinical Research Oncology from 2014 to 2016. Prior to joining Eisai, Dr. Voliotis served in various leadership positions at Bayer Healthcare from November 2001 to September 2014, including most recently as Vice President and Head of Global Development Specialty Medicine/Oncology. Dr. Voliotis has years of pharma and biotechnology expertise across the United States and Europe, with an emphasis on the radiopharmaceutical sector and experience in academic preclinical and clinical research as a Senior Consultant in Oncology and Head, Laboratory for Diagnostic Hematology and lmmunohematology at the University of Cologne Medical School. Dr. Voliotis serves as Senior Vice President of Clinical Development at Zeno Pharma, LLC. Dr. Voliotis received his M.D. from the University of Cologne Medical School,where he also completed his doctoral thesis in cellular biology and is Board certified in Medical Oncology & Hematology and Internal Medicine.
Positions
- Company NameRadiopharm Theranostics LimitedStock CodeRADXPositionChief Medical OfficerColleagues
- PEPaul Edward-Alexander HopperFounder & Executive Chairman
- RCRiccardo CanevariMD, CEO & Director
- ALAaron LauritaChief Financial Officer
- HGHitesh GoelHead of Project Management
- HLHester LarkinIndependent Non-Executive Director
- NPNoel P. DonnellyIndependent Non-Executive Director
- ITIan TurnerIndependent Non-Executive Director
